T he number of cases of ovarian cancer has reached 238,700, and it accounted for 151,920 deaths worldwide in 2012. 1 More than 70% of patients with ovarian cancer are diagnosed at an advanced stage. 2 Currently, the standard primary therapy for advanced disease involves the combination of maximal cytoreductive surgery with chemotherapy consisting of carboplatin and paclitaxel. 3 Although this standard chemotherapy initially yields a high response rate (980%), more than 70% of patients with advanced-stage epithelial ovarian cancer (EOC) experience a recurrence within 5 years, and their tumor develops drug resistance. 2, 4 Angiogenesis is one of the critical processes for the growth, invasion, and metastasis of solid tumors. 5, 6 The vascular endothelial growth factor (VEGF) family and its receptors (VEGFRs) are the members of one of the major pathways involved in tumor angiogenesis. The mammalian VEGF family of ligands is composed of 5 structurally related glycoproteins including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor. 7 Among these ligands, VEGF is the best characterized and seems to be a major mediator of tumor angiogenesis. 8 These VEGF ligands as well as placental growth factor uniquely bind to 3 structurally similar transmembrane receptor tyrosine kinases, referred to as VEGFR-1 (also known as fms-related tyrosine kinase 1), VEGFR-2 (also known as kinase insert domain receptor), and VEGFR-3 (also known as fms-related tyrosine kinase 4). The VEGF binds to both VEGFR-1 and VEGFR-2, which are found mainly on vascular endothelial cells. The VEGFR-2, which has a predominant role, mediates VEGF-induced angiogenic effects and vascular permeability effects, whereas the exact role of VEGFR-1 in angiogenesis is unclear. The VEGFR-3 preferentially binds VEGF-C and VEGF-D and has been reported to play an important role in lymphangiogenesis.
Recently, various molecular targeted agents have been developed and used in the treatment of a variety of malignancies, including EOC. 5, 9 Bevacizumab is a recombinant humanized monoclonal IgG antibody that targets VEGF-A and shows clinical benefit in patients with colorectal cancer and nonYsmall cell lung cancer. 5 In phase III trials, patients with advanced EOC who received standard combination chemotherapy plus bevacizumab with maintenance bevacizumab had significantly longer progression-free survival than those who received chemotherapy alone. 10, 11 Bevacizumab, when given with chemotherapy and continued as maintenance therapy, also yielded improvement in progression-free survival in patients with recurrent EOC. 12, 13 Besides the studies that focused on VEGF overexpression in tumor tissue samples to identify its value as a diagnostic or prognostic biomarker, 14 a number of studies that focused on serum VEGF-A have been published. 15 Advantages of a serum biomarker are (1) samples can be collected noninvasively from patients and (2) physicians can monitor changes in tumor biology by repeating the test throughout treatment. However, there have been few reports on concomitant detection of both ligands and its soluble receptors in serum samples from patients with EOC. Therefore, we conducted the present study to explore the utility of serum VEGFs and receptors and to evaluate their utility as prognostic biomarkers of EOC.
MATERIALS AND METHODS

Patients and Sample Collection
A total of 128 patients with EOC, who were consecutively treated at Tottori University Hospital between 2006 and 2012, were included in the present study. Patients with borderline malignancy were excluded. All patients underwent initial surgery followed by platinum-and taxane-based chemotherapy. Patients whose malignancy was considered to be unresectable during initial surgery received a few cycles of chemotherapy and then had interval debulking surgery if they responded to the chemotherapy. Patients were monitored for survival for a median duration of 57 months (range: 2Y112 months). Written informed consent was obtained from all participants, and the study was approved by the institutional review board of Tottori University Hospital.
Blood samples for analysis of VEGF/VEGFRs were collected before initial surgery. Samples were left to coagulate for 30 to 60 minutes, followed by centrifugation. The serum samples were aliquoted and immediately stored at j80-C. Tumor samples were collected from non-necrotic cancer tissue during initial surgery, rinsed with phosphate-buffered saline, and stored at j80-C before analysis. Ascites volume was measured during the surgery.
Enzyme-Linked Immunosorbent Assays
Serums VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2 concentrations were measured with the Quantikine Human VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2 kits (R&D Systems, Minneapolis, Minn). Serum samples were diluted 5-fold for VEGF-C determinations. Working standards were prepared according to the manufacturer's instructions. A total of 100 KL of Assay Diluent RD1W was added into a 96-well plate coated with a monoclonal antibody against each growth factor or soluble receptor. Serum samples, standards, and controls were dispensed in duplicate subsequently and incubated for 120 minutes at room temperature. The plate was washed 3 times in wash buffer. A volume of 200 KL of each VEGF/VEGFR conjugate was added to each well and incubated for 120 minutes. Washings were repeated. A volume of 200 KL of substrate solution provided with the kit was added in the dark, and the reaction was stopped after 30 minutes of incubation. Bound VEGF/VEGFRs were detected by measuring the absorbance at 450 nm in a photometer, and the concentration was determined from the standard curve. All samples were examined in triplicate, and the mean values were used for statistical analysis.
Real-Time Reverse Transcription Polymerase Chain Reaction
Messenger RNA (mRNA) expression of VEGF-A was determined with real-time reverse transcription polymerase chain reaction (RT-PCR). Total RNA was isolated from frozen tumor tissue using the RNeasy Mini Plus Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Complementary DNAwas synthesized from the isolated RNA by RT with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif ). Quantitative real-time PCR was performed using TaqMan Gene Expression Master Mix (Applied Biosystems) with specific primers and TaqMan probes for the target genes and for the endogenous control gene (VEGF-A, Hs00900054_m1 and GAPDH, Hs99 999905_m1).
The amplifications were carried out in a 20-KL volume in triplicate on a Mastercycler ep realplex (Eppendorf, Hamburg, Germany). The cycling parameters were 50-C for 2 minutes and 95-C for 10 minutes followed by 50 cycles of PCR at 95-C for 15 seconds and 60-C for 1 minute. The calculations for determining the relative level of gene expression were performed using the cycle threshold method. The mean cycle threshold values from the triplicate measurements were used to calculate the relative expression of VEGF-Awith normalization to GAPDH via the 2 j$$Ct method.
Immunohistochemistry
A part of each sample was fixed with 10% formalin and embedded in paraffin. For routine histologic studies, 3-Kmthick sections were stained with hematoxylin and eosin. After the sections were deparaffinized and endogenous peroxidase activity was blocked, they were pretreated with citrate buffer (0.01 M, pH 6.0) in a water bath for 40 minutes at 100-C. Thereafter, the sections were incubated at 4-C overnight with a rabbit polyclonal antibody against VEGF-A (clone A-20; diluted 1:100, Santa Cruz Biotechnology, Santa Cruz, Calif ). To detect binding of the primary antibody, the sections were incubated with EnVision + Dual Link System-HRP Rabbit/ Mouse (Dako, Glostrup, Denmark) for 30 minutes and then with 3,3 ¶-Diaminobenzidine solution (liquid diaminobenzidine + substrate, imidazole-HCL, Glostrup, Denmark) for 5 minutes. Finally, the sections were counterstained with hematoxylin. For the negative control, the primary antibodies were replaced with phosphate-buffered saline. We used a section of colon cancer tissue as the positive control of VEGF-A.
To evaluate the staining of cancer cells, a semiquantitative scoring method called the immunoreactive score (IRS) was performed according to Remmele and Stegner. 16 The IRS is obtained by the product of intensity of immunostaining (none = 0; weak = 1; moderate = 2; strong = 3) and percentage of positive tumor cells (none = 0; 1%Y10% = 1; 11%Y50% = 2; 51%Y80% = 3; 980% = 4).
Statistical Analysis
All statistical analyses were performed with Prism version 5 (GraphPad Software Inc, San Diego, Calif ) and JMP version 11 program (SAS Institute Inc, Cary, NC). Because the Shapiro-Wilk test for normality indicated that serum concentrations of VEGF/VEGFRs were not normally distributed, the Mann-Whitney U test was applied to investigate the significance of differences in VEGF/VEGFRs according to each clinicopathologic variable. The Spearman rank correlation test was performed to examine the relationship between ascites volume and VEGF/VEGFRs. Patient survival distribution was calculated using the Kaplan-Meier method. The significance of the survival distribution in each group was tested by the log-rank test. Multivariate analysis was performed to fit a Cox proportional hazards model. A P value of G0.05 was considered statistically significant.
RESULTS
One hundred twenty-eight patients with EOC were included in our study. The median age at initial diagnosis was 61 years (range: 29Y86 years Table 1 .
Median levels of serum VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2 were 279 (0Y1771), 4856 (1134Y15537), 395 (61Y2016), and 7065 (2815Y11652) pg/mL, respectively (Fig. 1A) . The levels of VEGF-A and VEGFR-1 in patients with FIGO stage III/IV disease were significantly higher than the levels in those with stage I/II disease. On the other hand, the level of VEGFR-2 in stage III/IV disease was significantly lower than that in stage I/II disease ( Table 2 ). The levels of VEGF-A and VEGF-C in patients with serous carcinoma were significantly higher than the levels in those with other histologic subtypes. On the other hand, the level of VEGFR-2 in patients with serous carcinoma was significantly lower than the level in patients with other histologic subtypes. The level of VEGF-A in patients with lymph node involvement was significantly higher than that in patients without it. We also found significant positive correlations between VEGF-A or VEGFR-1 levels and the volume of ascites. A negative correlation between VEGFR-2 and the volume of ascites was observed (Fig. 1B) .
At the end of the follow-up, 54 (42%) patients had died. For survival analysis, we set the cutoff value of VEGF/VEGFRs at the median level. The estimated 5-year overall survival (OS) rate and median survival time of patients with high VEGF-A levels (higher than the median level) were 41.8% and 55.6 months, respectively. The estimated 5-year OS rate and median survival time of patients with low VEGF-A levels were 61.7% and 83.3 months, respectively. The OS of patients with high VEGF-A levels was significantly lower than those with low levels (Fig. 2A) . The estimated 5-year OS rate and median (Table 3) .
We examined mRNA expression of VEGF-A in tumor tissue for comparison with serum VEGF-A levels. Total RNA of sufficient quality and quantity for real-time RT-PCR could be obtained from fresh frozen tissue samples in 30 of 128 cases. Therefore, we also examined these 30 cases for the immunohistochemical expression of VEGF-A. Relative mRNA levels expressed as the 2 j$$Ct value ranged from 1 to 604.7 (mean and SD: 40.4 and 154.9, respectively). The relative FIGURE 1. A, Distribution of serum concentrations of VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2. B, Because normality was rejected by the Shapiro-Wilk test, the Spearman rank correlation test was performed to examine the relationship between ascites volume and serum VEGF/VEGFRs. There were significant positive correlations between VEGF-A or VEGFR-1 levels and the volume of ascites and a negative correlation between VEGFR-2 and the volume of ascites. 2 . A, The OS of patients with high VEGF-A levels was significantly lower than that in those with low levels, and the OS of patients with low VEGFR-2 levels was significantly lower than that in those with high levels. But there were no significant relationship between OS and VEGF-C and VEGFR-1. B, Immunohistochemistry revealed that the VEGF-A protein was expressed mainly in cancer cells. Representative sections of stage IIIc, high-grade serous carcinoma scored as IRS: 12 (Â40).
mRNA levels of VEGF-A tended to be lower in patients with advanced disease, serous histology, or massive ascites (Table 4) . Tumor mRNA levels of VEGF-A showed a weak negative correlation with serum VEGF-A levels, but this was not significant (R = j0.2147, P = 0.2546). The VEGF-A proteins were observed strongly in cancer cells and weakly in stromal cells by immunohistochemical analysis (Fig. 2B) . We did not find any significant correlation between the IRS values and serum levels (R = 0.07475, P = 0.6946).
DISCUSSION
In the present study, we have investigated the expression of VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2 in the serum of patients with EOC. There have been few reports indicating that serum VEGF-A remains an independent prognostic factor after using multiple VEGF/VEGFRs concomitantly detected in serum samples as explanatory variables in multivariate analysis. Our results demonstrated that both high VEGF-A and low VEGFR-2 predict significantly worse OS, and that serum VEGF-A is an independent prognostic factor for OS in patients with EOC.
A meta-analysis that aimed to explore the association between VEGF-A overexpression and survival outcomes in EOC patients has been performed by Yu et al. 15 They reviewed 21 studies that detected tissue VEGF-A and 11 studies that detected serum VEGF-A. Survival data could be extracted from 6 of the 11 studies, and they were included in the final analysis. The median sample size of each study was 58 (range: 41Y101). Elevated serum VEGF-A was significantly associated with poor OS (HR 2.21, 95% CI [1.57Y3.13]). We examined the samples from 128 patients and showed that a similar association exists (HR 2.01, 95% CI [1.13Y3.63]). As for tissue VEGF-A in their meta-analysis, 10 of 21 studies were eligible, and our previous study was also included in the analysis. 14 Unfortunately, there was significant heterogeneity due to stage distribution. The HR from the subgroup analysis from 2 studies, where predominantly early-stage patients were included, was 6.13 (95% CI [2.47Y15.26]), whereas the HR for all patients was 1.70 (95% CI [1.01Y2.87]). Therefore, they suggested that serum VEGF-A was a more sensitive prognostic marker than tissue expression of VEGF-A.
In addition to VEGF-A, Sallinen et al 17 also examined serum angiopoietin (Ang)-1, Ang-2, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in 75 patients with EOC and concluded that serum Ang-2 predicted poor OS most accurately. Similar to our data, they also reported that elevated VEGF-A and low level of VEGFR-2 were significant predictors of poor OS in univariate analysis. Nevertheless, none of the angiogenic serum markers have been proven to be an independent prognostic factor for OS. Ebos et al 18 have shown in a preclinical model that plasma VEGFR-2 levels decrease with tumor growth, and that tumor-derived VEGF causes ligand-induced downregulation of VEGFR-2 from the cell surface. This may explain the worse prognosis for patients with lower serum VEGFR-2 levels.
The VEGF-C is found to be associated with lymph node metastasis in other malignancies. Cheng et al 19 reported that serum level of VEGF-C was correlated with lymph node metastasis in patients with ovarian cancer. On the contrary, the present study did not show any correlation between them. These 2 studies were comparable in terms of sample size, stage distribution, and frequency of serous histology. One possible explanation is the differential distribution of other histology. Our study includes more clear cell (18.7%) and less mucinous type (8.6%) than Cheng's study (4.6% and 20.2%, respectively). Whether the role of VEGF-C in lymph node metastasis is different between clear cell and mucinous tumor has to be elucidated by future studies including a larger cohort of these tumors.
There are few reports evaluating the relationship between serum VEGF levels and tumor VEGF expression. Poon et al 20 examined both serum levels and tumor expression of VEGF in 60 patients with hepatocellular carcinoma and showed that strong tumor immunostaining of VEGF was associated with higher serum VEGF/platelets. They also showed significant positive correlation between serum VEGF/platelets and tumor VEGF mRNA. 20 The present study showed negative correlation between tumor expression of VEGF-A mRNA and serum levels of VEGF-A, albeit not significantly. One plausible explanation for this discrepancy is tumor heterogeneity. Although serum levels can be affected by all lesions, we only evaluate mRNA or protein expression as a snapshot of the tumor. A higher proportion of stage III/IV disease in tumor samples than in serum samples may support this interpretation (66.7% [20/30] vs 57.8% [74/128]). Another explanation is the smaller sample size of our data.
The US Food and Drug Administration and the European Medicines Agency approved bevacizumab for EOC as a result of several randomized phase III studies showing the efficacy of bevacizumab. 7Y10 The combination of bevacizumab and standard chemotherapy in patients with EOC is becoming a onesize-fits-all approach because a biomarker that predicts the sensitivity of the tumor has not yet been identified. Therefore, patient selection using a predictive biomarker is needed from the perspective of cost-effectiveness.
Because the present study does not include patients treated with bevacizumab, we could not know whether serum VEGF-A is a predictive biomarker for the efficacy of bevacizumab. Sample size and study design are also limitations of our study. A larger sample size and a prospective design may provide more reliable or conclusive evidence.
We showed that both a high level of serum VEGF-A and a low level of serum VEGFR-2 predict significantly worse OS, and that serum VEGF-A is an independent prognostic factor for OS in patients with EOC. These results imply that serum VEGF-A is a potential prognostic biomarker for EOC. Further study to validate the data and to determine an appropriate cutoff value is needed. In addition, the hypothesis that serum VEGF-A is a predictive biomarker for bevacizumab should be tested by collecting samples from patients treated with the agent.
